Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016561 · ClinicalTrials.gov registry record · NA
Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01016561: Clinical Trial NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01016561 is a NA study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01016561, a NA study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy.
Primary Outcome
Feasibility will be defined if no greater than 10% of patients experience one of the following events: a) patient is unable to tolerate 50% of MRI-based brachytherapy treatments and b) patient experiences any grade 4 acute ("early") non-hematologic toxicity attributed to brachytherapy. Acute toxicity occurs within 60 days of therapy.
Interventions
- RADIATION intensity-modulated radiation therapy
- RADIATION 3-dimensional conformal radiation therapy
- RADIATION external beam radiation therapy
- RADIATION intracavitary balloon brachytherapy
- RADIATION radiation therapy treatment planning/simulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-07 |
| Est. Completion | 2016-12 |
| Phase | NA |
Why NCT01016561 stopped before completion
NCT01016561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT01016561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01016561 about?
NCT01016561 is a clinical study titled "Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer". Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor c...
What is the current status of trial NCT01016561?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2009-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01016561?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), 3-dimensional conformal radiation therapy (RADIATION), external beam radiation therapy (RADIATION), intracavitary balloon brachytherapy (RADIATION), radiation therapy treatment planning/simulation (RADIATION).
Who is sponsoring clinical trial NCT01016561?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01016561's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia